<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We enumerated programmed <z:hpo ids='HP_0011420'>death</z:hpo> 1 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1)-positive follicular helper T cells, a potentially important regulator of immune response, in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment of a series of 91 newly diagnosed follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> managed at a single institution </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical data were obtained for sex, age, Follicular <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> International Prognostic Index (FLIPI) risk group, presence of bulky disease, presence of B symptoms, and overall survival </plain></SENT>
<SENT sid="2" pm="."><plain>Immunohistochemical staining for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1 was performed on tissue microarray sections, and the mean number of follicular <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1-positive cells per 9 high-power fields (1000Ã—, 3 follicles with 3 fields per follicle) was quantified </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0023434" disease_type="Neoplastic Process" abbrv="BCLL">B-cell CLL</z:e>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> 2 (BCL-2) expression, CD68(+) extrafollicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-associated macrophages, and forkhead box P3 (FOXP3)+ regulatory T cells were evaluated as reported previously </plain></SENT>
<SENT sid="4" pm="."><plain>Ninety-one patients were evaluated, with a median age at diagnosis of 58 years and median survival of 11.6 years </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1-positive cells correlated with the number of FOXP3+ regulatory T cells (P = .01) </plain></SENT>
<SENT sid="6" pm="."><plain>On multivariate analysis, independent poor prognostic factors were age 55 years or greater (hazard ratio, 2.77; 95% confidence interval, 1.34-5.73; P = .006), bulky disease (hazard ratio, 2.27; 95% confidence interval, 1.03-5.00; P = .04), CD68(+) extrafollicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-associated macrophages greater than 16.8 cells/high-power field (hazard ratio, 2.15; 95% confidence interval, 1.14-4.06; P = .02), and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1-positive cells greater than 35.6 cells/high-power field (hazard ratio, 1.98; 95% confidence interval, 1.09-3.60; P = .03) </plain></SENT>
<SENT sid="7" pm="."><plain>These factors allowed construction of a risk score defining 3 distinct prognostic groups with 10-year overall survival of 85%, 60%, and 15% </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-1-positive follicular helper T cells and CD68(+) extrafollicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-associated macrophages appear to predict overall survival in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and our findings support strategies aimed at modulating their function in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Future studies, performed prospectively on uniformly treated patient cohorts, should be performed to validate these findings </plain></SENT>
</text></document>